The Case For NTD and S2: Prevalence and Protectiveness of Antibodies Towards SARS-CoV-2 Non-RBD Spike Epitopes

The Case For NTD and S2: Prevalence and Protectiveness of Antibodies Towards SARS-CoV-2 Non-RBD Spike Epitopes

Introduction Since the emergence of SARS-CoV-2, the causative agent of COVID-19, many researchers continue to focus their efforts on the discovery of potent neutralizing antibodies that would prove useful in the design of COVID-19 countermeasures such as vaccines and therapeutics. To date, most vaccines or therapeutics in clinical trials or…

SARS-CoV-2 Variants: An Emerging Landscape of Therapeutic Targets

SARS-CoV-2 Variants: An Emerging Landscape of Therapeutic Targets

In recent months, viral strains of SARS-CoV-2 have been detected that are unusual in that they have accumulated mutations in the virus’ genetic code that diverges from the wild-type (WT) Wuhan SARS-CoV-2 strain. These viral strains with accumulated genome mutations are known as SARS-CoV-2 variants. As SARS-CoV-2 variants continue to…